🇺🇸 FDA

Intelligence · Clinical Pipeline

Takeda Pipeline

All ClinicalTrials.gov programs at Takeda — phase, modality, and trial IDs.

Programs
1,179

Quick answer

Takeda has 1,179 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. SHP640

    Takeda

    Adenoviral Conjunctivitis

    phase 3 small molecule terminated

    2 trials

  2. SHP640

    Takeda

    Bacterial Conjunctivitis

    phase 3 small molecule completed

    1 trial

  3. SOTYKTU 6 mg film-coated tablets, Matching Placebo for Deucravacitinib, SOTYKTU 6 mg film-coated tablets, SOTYKTU 6 mg film-coated tablets, ZASOCITINIB, SOTYKTU 6 mg film-coated tablets, Matching Placebo for TAK-279

    Takeda

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  4. SPD422 (anagrelide hydrochloride)

    Takeda

    Essential Thrombocythemia (ET)

    phase 3 small molecule completed

    1 trial

  5. SPD465

    Takeda

    Attention-Deficit/Hyperactivity Disorder

    phase 3 small molecule completed

    2 trials

  6. SPD476

    Takeda

    Ulcerative Colitis

    phase 3 small molecule completed

    1 trial

  7. SPD476 (1.2g)

    Takeda

    Diverticulitis

    phase 3 small molecule completed

    1 trial

  8. SPD476 (mesalazine)

    Takeda

    Colitis, Ulcerative

    phase 3 small molecule completed

    1 trial

  9. SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine

    Takeda

    Ulcerative Colitis

    phase 3 small molecule completed

    1 trial

  10. SPD476, MMX™ mesalazine, 1.2g extended release tablet

    Takeda

    Diverticulitis

    phase 3 small molecule completed

    1 trial

  11. SPD489

    Takeda

    ADHD

    phase 3 small molecule terminated

    1 trial

  12. SPD489

    Takeda

    Schizophrenia

    phase 3 small molecule terminated

    1 trial

  13. SPD489

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    2 trials

  14. SPD489 (Lisdexamfetamine dimesylate)

    Takeda

    Major Depressive Disorder

    phase 3 small molecule completed

    2 trials

  15. SPD489 (Lisdexamfetamine dimesylate)

    Takeda

    Binge Eating Disorder

    phase 3 small molecule completed

    2 trials

  16. SPD489 (Lisdexamfetamine dimesylate) + Antidepressant

    Takeda

    Major Depressive Disorder

    phase 3 small molecule terminated

    1 trial

  17. SPD489 40mg

    Takeda

    Schizophrenia

    phase 3 small molecule terminated

    1 trial

  18. SPD489 Low-Dose

    Takeda

    Negative Symptoms of Schizophrenia

    phase 3 small molecule terminated

    1 trial

  19. SPD489 low dose range (40mg, 80mg, and 100mg)

    Takeda

    Schizophrenia

    phase 3 small molecule terminated

    1 trial

  20. SPD503 (1 mg)

    Takeda

    Attention Deficit Disorder With Hyperactivity

    phase 3 small molecule completed

    1 trial

  21. SPD503 (Guanfacine hydrochloride)

    Takeda

    ADHD

    phase 3 small molecule completed

    1 trial

  22. SPD503 (Guanfacine hydrochloride) (2 mg)

    Takeda

    Attention Deficit Disorder With Hyperactivity

    phase 3 small molecule completed

    1 trial

  23. SPD503-AM

    Takeda

    ADHD

    phase 3 small molecule completed

    1 trial

  24. SYR-322-MET

    Takeda

    Clinical Pharmacology

    phase 3 small molecule completed

    1 trial

  25. SYR-472

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    5 trials

  26. SYR-472

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  27. Soticlestat

    Takeda

    Dravet Syndrome (DS)

    phase 3 small molecule terminated

    3 trials

  28. Spironolactone

    Takeda

    Atrial Fibrillation

    phase 3 small molecule active

    1 trial

  29. TAK-003

    Takeda

    Dengue Fever

    phase 3 mab completed

    1 trial

  30. TAK-019

    Takeda

    Coronavirus Disease (COVID-19)

    phase 3 mab completed

    1 trial

  31. TAK-279

    Takeda

    Generalized Pustular Psoriasis

    phase 3 small molecule active

    1 trial

  32. TAK-279

    Takeda

    Plaque Psoriasis

    phase 3 small molecule active

    3 trials

  33. TAK-330

    Takeda

    Coagulation Disorder

    phase 3 small molecule active

    1 trial

  34. TAK-438

    Takeda

    Non-erosive Gastroesophageal Reflux Disease

    phase 3 small molecule completed

    1 trial

  35. TAK-438

    Takeda

    Gastric Ulcer

    phase 3 small molecule completed

    4 trials

  36. TAK-438

    Takeda

    Gastric Ulcers

    phase 3 small molecule completed

    4 trials

  37. TAK-438

    Takeda

    Erosive Esophagitis

    phase 3 small molecule completed

    4 trials

  38. TAK-438

    Takeda

    H. Pylori Infection

    phase 3 small molecule completed

    1 trial

  39. TAK-438

    Takeda

    Duodenal Ulcer

    phase 3 small molecule completed

    2 trials

  40. TAK-536

    Takeda

    Hypertension

    phase 3 small molecule completed

    1 trial

  41. TAK-536CCB

    Takeda

    Grade I or II Essential Hypertension

    phase 3 small molecule completed

    1 trial

  42. TAK-536TCH tablet

    Takeda

    Essential Hypertension

    phase 3 small molecule completed

    1 trial

  43. TAK-559

    Takeda

    Diabetes Mellitus

    phase 3 small molecule terminated

    3 trials

  44. TAK-559 and glyburide

    Takeda

    Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  45. TAK-559 and insulin

    Takeda

    Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  46. TAK-559 and metformin

    Takeda

    Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  47. TAK-583

    Takeda

    Neuralgia, Postherpetic

    phase 3 small molecule completed

    1 trial

  48. TAK-625

    Takeda

    Alagille Syndrome (ALGS)

    phase 3 small molecule completed

    1 trial

Frequently asked questions

How many pipeline programs does Takeda have?

1,179 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.